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Abstract 
The past decade has seen a rapid growth in omics technologies. Genome-wide association studies 
(GWAS) have uncovered susceptibility variants for a variety of complex traits. However, the 
functional significance of most discovered variants are still not fully understood. On the other hand, 
there is increasing interest in exploring the role of epigenetic variations such as DNA methylation in 
disease pathogenesis. In this work, we present a general framework for epigenome-wide association 
study and integrative analysis with the transcriptome based on GWAS summary statistics and data 
from methylation and expression quantitative trait loci (QTL) studies. The framework is based on 
Mendelian randomization, which is much less vulnerable to confounding and reverse causation 
compared to conventional studies. The framework was applied to five complex diseases. We first 
identified loci that are differentially methylated due to genetic variations, and then developed several 
approaches for joint testing with the GWAS-imputed transcriptome. We discovered a number of novel 
candidate genes that are not implicated in the original GWAS studies. We also observed strong 
evidence (lowest p = 2.01e-184) for differential expression among the top genes mapped to 
methylation loci. The framework proposed here opens a new way of analyzing GWAS summary data 
and will be useful for gaining deeper insight into disease mechanisms.  
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Introduction  
The past decade has seen a rapid growth in omics technologies. Genome-wide association studies 
(GWAS) have been successful in unraveling susceptibility variants for a variety of complex traits1. 
However, the functional significance of most discovered variants are still not fully understood. On the 
other hand, high-throughput technologies have enabled the study of gene expression and epigenetic 
changes on a genome-wide scale. Integrative analyses of these various types of data will deepen our 
understanding of disease pathophysiologies and ultimately lead to more effective treatments.  
 
  DNA methylation is a key epigenetic mechanism which is implicated in the regulation of gene 
expression2. Recent studies also suggested that DNA methylation may be involved in other functions 
such as promotor usage and alternative splicing2,3. With the recent advent of new high-throughput 
arrays, DNA methylation can now be studied genome-wide in a hypothesis-free manner. Such 
epigenome-wide or methylome-wide association studies (EWAS/MWAS) has been applied to study 
numerous diseases and many methylation sites have been found to be associated with disease status4. 
Nevertheless, the interpretation of EWAS findings is often not straightforward. Reverse causation is 
possible, that is, methylation changes can be the direct or indirect consequences of a disease instead of 
being its cause5. In addition, associations between methylation and disease can be due to confounding 
factors, such as smoking and other unknown variables that could not be completely adjusted for4.  
 
In view of these limitations, in this study we present a Mendelian randomization (MR) based 
analytic framework to study the relationships between methylation and disease. A genetic proxy is 
used to represent methylation and its association with disease is then investigated. MR is an 
established method to study causal relationships between exposures and outcomes6. MR has been 
previously proposed as a way to study the relationships of epigenetic processes to disease5, but to our 
knowledge no studies have applied this approach in a methylome-wide level. In the paper the authors 
suggested a more complex two-step design, in which one first uses a genetic proxy for an 
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environmental exposure (e.g. smoking) to assess the causal relationship between exposure and disease, 
and then uses another genetic proxy for methylation to elucidate the relationship between methylation 
and disease5. In this work we focus on the one-step approach. In essence, we studied the genetically 
controlled component of methylation and assessed the association of methylation levels with complex 
traits or diseases. We note that an association can be due to causality (i.e. methylation alterations 
causing the disease), pleiotropy [i.e. the proxy genetic variant(s) independently affect methylation and 
disease risks], or a combination of both. As will be discussed in a later section, we do not focus on 
distinguishing these possibilities in this work.  
 
The MR approach for methylation studies is less vulnerable to confounding and reverse causation 
than conventional methods6,7. And importantly, this approach only requires summary statistics from 
GWAS and methylation quantitative trait loci (meQTL) studies. With the increased availability of 
GWAS summary results (e.g. in LD Hub8) and rising sample sizes from meta-analyses, this approach 
leverages the power of GWAS to unravel methylation changes linked to complex diseases. To our 
knowledge, this is the first study to investigate methylome-wide associations based on GWAS 
summary data.  
 
We developed a framework to integrate the methylation results with the GWAS-imputed 
transcriptome, and proposed several measures to assess the significance of a gene based on a joint 
analysis of GWAS-derived methylome and transcriptome associations. We applied the approach to 
five complex diseases and found a remarkable tendency (lowest p = 2.01e-184) towards differential 
expression within the top methylation loci. We also revealed a number of novel genes for the diseases 
under study.  
 
  A few previous studies have interrogated alternative omics profiles from GWAS data. The majority 
focused on the transcriptome, for example Gamazon et al.9 proposed imputation of expression levels 
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based on training in a reference transcriptome dataset. The method was extended to the use of only 
summary statistics for imputation, including TWAS10 and MetaXcan11. These two methods employed 
mixed effects models and elastic net regression respectively by default to train prediction models. 
However, in this study we relied on top summary statistics from meQTL studies (instead of having the 
original genotype data) and MR is a computationally simple and flexible approach that does not 
require training with raw data. In a related work, Zhu et al. proposed SMR12, a MR-based approach 
which integrated GWAS summary data with expression QTL results. We studied the methylome in 
this work instead and compared to SMR, we did not restrict the analyses to only the top QTL in each 
test. We also extended our analysis to integrate methylome and transcriptome data.  
 
Methods 
The Mendelian Randomization approach  
Mendelian randomization (MR) involves the use of genetic variants as instruments to interrogate the 
relationship between an exposure and an outcome6. Genetic variation serves as a natural way of 
“randomization” of individuals such that confounding is much less likely. Details of different MR 
methods could be found elsewhere7. In brief, assume that we have j genetic variants (G1, G2…Gj) 
acting as instrument variables, X is the exposure (risk factor), Y is the outcome,βXj is effect size of Gj 
to X andβYj is the effect of Gj to Y. The causal effect of X on Y can be estimated by ˆ ˆ ˆ/IVj Yj Xj    
under certain assumptions. Note that X refers to methylation levels and Y refers to the studied disease 
or trait in our case. The assumptions include: (1) The genetic variant is independent of confounders; 
(2) The genetic variants is associated with the exposure; and (3) The genetic variant have no effect on 
the outcome when the exposure remains fixed, i.e. no pleiotropic effects. It is often difficult to fully 
exclude pleiotropy in actual scenarios. In the presence of pleiotropy, the effect size becomes  
/
jj j X
     , where j is the effect size of the pleotropic effects
13 and  is the causal effect. 
Recently new methods such as Egger regression13 have been developed to produce consistent casual 
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effect estimates when pleiotropy is present. However, in this study the number of instrumental 
variants is small (mostly less than three) and hence we did not focus on separating causal effects from 
pleiotropy.  
    
By the delta method, the variance of the effect estimate of X on Y based on an instrumental variable 
IVj is  
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up to second-order terms14. In the inverse-variance weighted method, only the first-order term is 
retained15. We kept the second-order term in this study and combined the effects of different genetic 
variants by a fixed-effects approach. The aggregate effect size estimate of X on Y (i.e. methylation on 
disease state or trait values) can be expressed by: 
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We used the implementation in the R package MR-base16. The above algorithm was repeated for each 
methylation probe available in the meQTL dataset and repeated for each time-point (birth, childhood, 
adolescence and middle age).  
 
GWAS and methylation QTL data 
We performed methylome-wide association studies based on MR for five complex diseases, namely 
schizophrenia (SCZ)17, Alzheimer’s disease (AD)18, coronary artery disease (CAD)19, type 2 diabetes 
mellitus (DM)20 and inflammatory bowel disease (IBD)21. GWAS summary statistics were derived 
from meta-analyses of large sample sizes and study details were given in the attached references. For 
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methylation data, we extracted the results from a recent methylation QTL study known as ARIES22,23. 
The study investigated the influence of genetic variations on methylation from cord blood or 
peripheral blood samples across the life course by the Illumina Infinium HumanMethylation450 
array23. They identified methylation QTLs (meQTLs) at five life stages, namely birth, childhood 
(mean age 7.5 years), adolescence (mean age 17.1 years), pregnancy (mean age 29.2 years) and 
middle age (mean age 47.5 years). The sample size was relatively large (N ranging from 742 to 837). 
The results are publicly available and the independent top meQTL results (available at 
http://www.mqtldb.org/ and in the MR-base package16) were used in our study.   
 
  For SCZ and IBD, the median ages at onset are well below middle age24,25 and hence we only 
studied methylation at three time-points (birth, childhood and adolescence) while four time-points 
were considered for the other traits.  
 
Joint analysis with GWAS-imputed transcriptome 
As methylation can affect gene expression and the transcriptome is an integral part of disease 
pathogenesis, in the next step we imputed transcriptome based on GWAS summary results. We 
employed MetaXcan11 to impute expression changes in peripheral blood, in order to match with the 
tissue studied in the methylation QTL study. The DGN dataset26 was used as the reference 
transcriptome dataset. MetaXcan pre-trains a prediction model (elastic net by default) on the reference 
set and applies it to the summary GWAS results.  
 
   To jointly analyze methylome and transcriptome data, we adopted a gene-based approach. 
Methylation probes were annotated based on the documentation provided by the Illumina 
HumanMap450 manifest files. For multiple probes that mapped to the same gene, we employed the 
Simes method to combine the p-values. The Simes method tests for at least one non-null effect among 
all hypotheses and controls the type I error rate under positive regression dependency27. After 
7 
 
obtaining a gene-based p-value for methylation, we further combined it with the expression p-value 
from MetaXcan.   
 
We considered two types of hypotheses in this case. In the first scenario, the researcher may be 
interested in finding genes that are both differentially methylated and expressed. We proposed a 
simple hypothesis testing approach by taking the maximum p-value i.e. max(pmethylation, pexpression), 
which is proven to be valid under positive dependence28,29. In the second scenario, one may be 
interested to search for genes that are associated with disease in at least one kind of omics measure 
(expression or methylation). To put it in another way, the null hypothesis in the second scenario is the 
global null. The Simes method was used in this case to combine p-values.  
 
For the second scenario, we also developed an empirical Bayes approach, in line with the local 
false discovery rate (fdr) framework30 but adapted to the two-dimensional case. Here the null 
hypothesis (H0) is that both effects are null. Let z1 and z2 be the observed z-statistics corresponding to 
differential methylation and expression, we define the “co-fdr” as: 
1 2 0 0
0 1 1 2 2
1 2
( , | ) Pr( )
- Pr( | , )
( , )
f z z H H
co fdr H Z z Z z
f z z
      
Here 1 2 0( , | )f z z H is the probability density function (pdf) of z1 and z2 under the null, which was 
assumed to follow a bivariate normal distribution with unknown means and covariance. We estimated 
the unknown parameters by fitting a truncated bivariate normal distribution to the observed z-statistics, 
and obtained the maximum likelihood (MLE) estimates. By doing so we assumed that the central part 
of the observed distribution of z-statistics are mostly null, and a similar approach has been used by 
Efron to estimate the empirical null for one-dimensional z-statistics31. Following Efron, we set the 
cutoff z-value at 2, i.e. we used z-values between -2 and 2 to fit the truncated normal distribution. We 
set 0Pr( )H  (prior probability of null association) to be one to produce a conservative estimate of 
co-fdr. 1 2( , )f z z  was estimated by a multivariate kernel density function using the R package 
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“ks”32.  
 
Differential expression among the top methylation loci 
Within those methylation loci that passed the Bonferroni correction (for the total number of probes 
tested at each time-point), we tested whether the genes corresponding to these top methylation loci 
were also differentially expressed as a whole. We considered the genes that were mapped to at least 
one methylation loci and had expression test results available.  We collected the expression p-values 
of the top differentially methylated genes and combined them with the Fisher’s method and the Simes 
method.  
 
Methylation-expression associations among the top methylation loci 
Among the top methylation loci, we also tested for Pearson and Spearman correlations of the effect 
sizes of differential methylation and expression. As previous studies showed that the 
methylation-expression link is associated with the location of methylation2, methylation probes were 
grouped by both gene names and their locations (gene body, TSS1500 [1500 bp upstream of 
transcription start site], TSS200, first exon, 5’ or 3’ UTR) as annotated by the Illumina documentation 
file. If a gene was represented by multiple methylation probes or at different time-points, the mean 
effect size was used.  
 
Results  
Top methylation loci identified 
We observed a high correlation among the test results that overlapped across different life stages, 
consistent with the report by Gaunt et al. in the original meQTL study. We mapped all genome-wide 
significant SNPs in GWAS summary data (p < 5e-8) to genes using the R package Biomart, and 
compared them with the genes corresponding to our top methylation loci. Table 1 shows the 
methylation loci which passed the Bonferroni correction (for the total number of loci tested at each 
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time-point) and not implicated in the original disease GWAS. These results represent novel candidate 
genes and might warrant further follow-up studies. Note that the Bonferroni correction is conservative 
as there are correlations among the methylation probes. 
 
Joint testing with imputed transcriptome 
The top conjunction test results of methylation and expression using maximum p are shown in 
Table 2. Only the Bonferroni significant results are shown. It is worth noting that the maximum p 
method is simple and statistically valid but it does not consider the actual covariance structure so 
some power is lost in this regard. There are fewer results passing Bonferroni correction which could 
be due to inadequate power to detect such associations. However, genes showing evidence of both 
differential methylation and expression might represent more biologically plausible candidates for 
further functional studies.  
 
  Table 3 shows the top 10 genes with the lowest co-fdr for each trait in our analysis. The co-fdr can 
be directly interpreted as the probability that the gene shows no differential expression or methylation 
from the GWAS-based analysis. Both the co-fdr and Simes method test the global null hypothesis; 
hence low co-fdr tends to be associated with low Simes p-values and vice versa.  
 
Differential expression and methylation-expression associations among the top methylation loci 
We found that genes mapped to the top methylation loci (passing Bonferroni significance) also tended 
to be differentially expressed. The associations were remarkably strong, with the lowest p-value 
achieving 2.01e-184 (for IBD) (Table 4). The associations were also observed for all five traits under 
study. However we note that not all genes demonstrated such an association. One possible explanation 
for the enrichment of differential expression is that differential methylation results in transcriptomic 
changes, which in turns affect disease risk. This is biologically plausible given the evidence for 
methylation regulating expression33. However, we caution that our model cannot prove a causal 
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relationship between methylation and expression. The reverse is also possible (i.e. expression changes 
leading to differences in methylation levels)34. It is also possible that the same genetic variant(s) affect 
methylation, expression and disease risk separately and we will still observe both differential 
methylation and expression with respect to the disease. Hence one explanation for our observations is 
that disease susceptibility variants tend to influence gene expression and methylation together, more 
than expected by chance. Given the complexity of biological systems, it is possible the truth may 
involve a mixture of the above mechanisms, and may vary for individual genes and disease 
phenotypes.  
    
   We also examined correlations of effect sizes with regards to methylation and expression among 
the top differentially methylated loci. For schizophrenia, we observed a significant negative 
correlation (Pearson correlation -0.571, p = 1.79e-4; Spearman’s rho -0.522, p = 7.74e-4) (Table 5). 
We then performed a stratified analysis considering only methylation probes at the promotor region, 
which include TSS200 (200 base pairs away from the 5’ end of transcription start site), TSS1500 
(regions further away than TSS200 by up to 1300 base pairs), 5’UTR (5’untranslated region) and the 
first exon. Methylation in these regions was previously reported to be associated with repression of 
gene expression35. For schizophrenia, a negative correlation of effect sizes of methylation and 
expression was observed (Pearson correlation -0.61, p = 5.46e-3; Spearman’s rho -0.63, p = 4.71e-3) 
and a binomial test showed enrichment for associations in opposite signs (opposite signs in 15/19, 
one-tailed p = 0.010). For methylation probes at other regions, we observed a negative Pearson 
correlation of effect sizes but the association was weaker (Pearson correlation -0.54, p = 0.017); and 
no significant results was found for the Spearman correlation and binomial sign tests. When we 
repeated the analysis for the other diseases under study, we did not observe significant correlations or 
binomial sign test results. The significance of this observation is unknown. Wagner et al.33 reported 
complex relationships between methylation and expression, and that the strongest correlation was 
found in a group of developmentally important genes. Interestingly, schizophrenia is well-known to be 
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a neurodevelopmental disorder and the stronger methylation-expression link is broadly consistent with 
Wagner et al. It is worth noting that the numbers of top methylation loci were small (<10) for CAD, 
DM and AD, and these samples might be underpowered to detect any correlations.   
 
Discussion 
In summary, we propose a general framework for epigenome-wide association study and integrative 
analysis with the transcriptome using GWAS summary statistics. The framework is based on the 
Mendelian randomization methodology, adapted to a methylome-wide scale. By applying the 
framework to five complex diseases, we showed how this approach may help to identify differentially 
methylated loci and prioritize genes for further functional or other follow-up studies. In addition, we 
observed strong evidence for differential expression among the top genes mapped to methylation loci.  
 
  There are some limitations to this study. Firstly, as alluded to earlier, the current method does not 
prove causal relationships. It is difficult to differentiate pleiotropy from causation, especially with 
only a few number of instrumental genetic variants. Recently methods have been proposed to correct 
the bias due to pleiotropy13, but in the presence of few instrumental variables the results may not be 
reliable. Large-scale meQTL studies may enable more variants to be discovered and such 
bias-correction methods can potentially be applied. However, even if the differential methylation is 
due to pleiotropy, the associated gene or genetic variant might still represent a biologically important 
candidate for further studies. Conventional EWAS are not immune to associations due to pleiotropic 
effects either. Also, as the MR approach is less affected by confounding or reverse causation, the 
results from the MR-based EWAS can be used to prioritize findings from conventional EWAS for 
finding casual loci. 
 
  Another limitation is the tissue specificity. We used methylation and expression in the peripheral 
blood as a surrogate in this study. Obviously, the framework presented here is readily applicable to 
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any tissue types, if relevant summary statistics are available. Summary data for meQTLs are less 
readily available compared to eQTLs. Large-scale resources like GTEx36 which provides public 
access to eQTL information over a large range of tissues are still lacking for methylation. In addition, 
as argued by Zhu et al.12, the exact tissue type implicated in a disease may be unknown. For example, 
psychiatric disorders obviously involve the brain but there is growing evidence for the immune 
system to be implicated37,38.  
 
  The ability to detect associations with the MR approach will depend on the power of the original 
GWAS and QTL study. The method will become more powerful with increases in sample sizes. It is 
worth mentioning that the ARIES dataset only included females when studying methylation levels at 
middle age, and how well it can be generalized to adult males remain to be investigated.  
 
  Notwithstanding the above limitations, we believe the framework proposed here will be useful for 
researchers to gain insight into disease mechanisms, which might ultimately lead to improved 
treatment for complex diseases. This work also illustrates the potential of employing publicly 
available data, including large-scale GWAS and QTL studies, in integrating omics sources to achieve 
more in-depth understanding of complex traits and diseases.  
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Table 1  Methylation probes with mapped genes passing Bonferroni correction and not achieving genome-wide 
significance in the original GWAS meta-analysis 
Methylation Probe (time-point) cpg_chr cpg_pos cpg_gene nsnp b.fixed.delta pval.fixed.delta 
SCZ 
      
cg26536240 (Adolescence) 16 89509760 ANKRD11 1 0.092  1.12E-06 
cg16263627 (Childhood) 15 100339283 DNM1P46 1 -0.206  1.52E-07 
cg21290290 (Childhood) 1 2518275 FAM213B 1 0.233  1.95E-06 
cg08619954 (Childhood) 4 5526783 LINC01587 1 0.157  9.89E-07 
cg16492833 (Adolescence) 6 33679775 UQCC2 2 0.092  1.19E-06 
cg00658411 (Childhood) 16 4467558 CORO7 1 0.063  1.16E-06 
cg14092988 (Adolescence) 3 52407081 DNAH1 1 -0.065  3.66E-07 
cg06606381 (Adolescence) 12 133084897 FBRSL1 1 0.429  1.04E-13 
cg23656755 (Adolescence) 1 230203043 GALNT2 1 -0.201  2.38E-07 
cg10639394 (Childhood) 15 82640457 GOLGA6L10 2 0.171  1.09E-07 
cg01061553 (Adolescence) 12 110891467 GPN3 1 -0.120  1.85E-06 
cg18278486 (Adolescence) 6 26987575 LOC100270746 2 0.127  4.53E-08 
cg03959625 (Childhood) 15 84868606 GOLGA2P7 1 -0.167  5.39E-08 
cg19630374 (Adolescence) 17 18023558 MYO15A 1 -0.126  9.82E-07 
cg05725404 (Childhood) 16 58534157 NDRG4 3 -0.118  3.17E-09 
cg17372223 (Childhood) 3 52568218 NT5DC2 2 -0.089  1.15E-07 
cg02753903 (Childhood) 19 38943525 RYR1 1 -0.101  7.65E-07 
cg24247370 (Birth) 13 99142703 STK24 1 0.120  4.00E-07 
cg18393722 (Birth) 15 85113863 UBE2QP1 3 -0.100  4.46E-07 
       
AD 
      
cg18816397 (Middle age) 6 32489555 HLA-DRB5 2 0.154  7.51E-10 
cg15224348 (Middle age) 19 45543538 SFRS16 1 0.114  9.19E-08 
cg10853231 (Adolescence) 19 48111307 GLTSCR1 1 -0.131  2.05E-06 
       
CAD 
      
cg25035485 (Childhood) 2 21266500 APOB 2 0.132  8.45E-09 
cg03493300 (Childhood) 10 104813866 CNNM2 1 -0.063  2.17E-07 
cg25313468 (Adolescence) 4 57773308 REST 2 -0.106  2.32E-07 
cg24147428 (Childhood) 11 65409760 SIPA1 2 0.098  2.49E-07 
cg05180856 (Birth) 15 91428056 FES 1 0.167  9.29E-07 
       
DM 
      
cg11823178 (Adolescence) 8 41519399 ANK1 1 0.118  7.83E-07 
cg00908766 (Middle age) 1 109817496 CELSR2 2 -0.093  2.31E-06 
cg11879188 (Childhood) 9 136149908 ABO 2 0.131  4.30E-06 
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IBD 
      
cg18477569 (Birth) 6 90951134 BACH2 1 -0.096  1.32E-06 
cg09501687 (Childhood) 5 150169781 SMIM3 1 0.239  8.28E-09 
cg21582582 (Birth) 3 182698605 DCUN1D1 1 -0.186  3.89E-10 
cg10154826 (Birth) 6 17600994 FAM8A1 1 -0.209  1.13E-24 
cg14895029 (Childhood) 7 2775587 GNA12 2 0.115  1.40E-06 
cg23982607 (Adolescence) 1 1823379 GNB1 3 0.107  2.96E-07 
cg23216724 (Childhood) 6 167571584 GPR31 1 0.247  6.88E-07 
cg23283495 (Adolescence) 1 209979779 IRF6 3 0.120  6.00E-09 
cg01311341 (Adolescence) 22 25575246 KIAA1671 1 0.255  1.03E-07 
cg21574349 (Adolescence) 3 185080951 MAP3K13 1 -0.308  2.14E-08 
cg00580354 (Adolescence) 2 179296317 PRKRA 1 -0.387  1.95E-19 
cg04092800 (Childhood) 5 40681444 PTGER4 1 0.469  7.00E-09 
cg00271210 (Childhood) 6 167070053 RPS6KA2 1 -0.132  2.89E-10 
cg01358966 (Adolescence) 16 29118931 RRN3P2 1 0.348  1.18E-06 
cg13746518 (Adolescence) 9 137332241 RXRA 1 -0.350  5.98E-11 
cg15335139 (Childhood) 3 50242325 SLC38A3 1 -0.114  8.34E-07 
cg22887911 (Childhood) 3 44903730 TMEM42 1 -0.262  2.52E-09 
cg10500283 (Adolescence) 1 7913081 UTS2 2 0.131  1.98E-07 
cg21665057 (Adolescence) 3 196295764 WDR53 1 -0.195  6.67E-10 
Only methylation probes with mapped genes are shown. We used Biomart to map genome-wide significant SNPs to genes; 
in this table only the “new” associations that do not have a GWAS hit are shown. cpg_chr, chromosome of the CpG probe, 
cpg_pos, position of the CpG probe; nsnp, number of SNPs acting as instrumental variables;  b.fixed.delta, regression 
coefficient (effect size) from MR analysis using a fixed-effects model with variance estimated by the delta method; 
pval.fixed.delta, corresponding p-value from MR analysis.
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Table 2 All genes passing Bonferroni correction for the conjunction test of both differential methylation and 
expression (using maximum p)  
Cpg_gene Simes_methyl_p Expr_p Total_cpg Max_conj_p  Cpg_gene Simes_methyl_p Expr_p Total_cpg Max_conj_p 
SCZ 
     
IBD 
    
BTN3A2 7.89E-10 1.43E-18 1 7.89E-10 
 
HLA-DQB2 6.43E-13 2.98E-15 3 6.43E-13 
NMB 2.49E-09 1.94E-09 4 2.49E-09 
 
ORMDL3 1.23E-12 1.48E-12 4 1.48E-12 
ARL6IP4 7.19E-10 5.15E-09 3 5.15E-09 
 
ZGPAT 4.28E-11 1.35E-14 3 4.28E-11 
NDRG4 1.90E-08 3.08E-09 6 1.90E-08 
 
SLC22A5 8.96E-11 1.52E-12 2 8.96E-11 
KLC1 5.89E-08 8.83E-12 2 5.89E-08 
 
INPP5E 1.38E-10 2.25E-10 1 2.25E-10 
PSMA4 3.55E-08 6.15E-08 1 6.15E-08 
 
APEH 3.08E-10 4.02E-20 7 3.08E-10 
RPRD2 1.14E-09 1.19E-07 1 1.19E-07 
 
STMN3 7.35E-10 1.94E-12 5 7.35E-10 
ABCB9 1.25E-07 1.23E-10 1 1.25E-07 
 
LIME1 4.43E-09 8.13E-16 6 4.43E-09 
RERE 8.45E-08 3.51E-07 5 3.51E-07 
 
PTGER4 7.04E-09 1.32E-10 1 7.04E-09 
ITIH4 7.68E-07 6.79E-07 1 7.68E-07 
 
RNASET2 5.22E-09 7.60E-09 2 7.60E-09 
SNX19 1.38E-06 5.60E-11 2 1.38E-06 
 
IKZF3 1.08E-09 1.43E-08 1 1.43E-08 
GATAD2A 1.52E-06 1.42E-07 3 1.52E-06 
 
ARPC2 1.55E-07 3.84E-08 2 1.55E-07 
GPN3 1.85E-06 1.37E-06 1 1.85E-06 
 
GSDMB 1.87E-07 8.27E-14 1 1.87E-07 
CYP2D6 1.92E-06 1.01E-07 1 1.92E-06 
 
ZGLP1 2.28E-07 2.27E-13 1 2.28E-07 
FES 6.13E-07 2.01E-06 1 2.01E-06 
 
UBE2L3 2.42E-07 2.35E-09 1 2.42E-07 
NEK4 2.44E-06 7.35E-11 1 2.44E-06 
 
PGAP3 7.00E-07 5.34E-08 2 7.00E-07 
PITPNM2 4.74E-06 6.64E-06 2 6.64E-06 
 
CUL2 1.67E-06 4.86E-11 1 1.67E-06 
ZSCAN16 6.82E-06 4.64E-22 2 6.82E-06 
 
IL1RL1 2.45E-06 1.03E-09 1 2.45E-06 
NAGA 7.41E-06 3.31E-08 1 7.41E-06 
 
IL27 9.05E-08 3.20E-06 1 3.20E-06 
C22orf32 7.59E-06 3.60E-07 2 7.59E-06 
 
GNB1 5.92E-07 3.58E-06 2 3.58E-06 
SH3RF1 8.29E-06 1.19E-07 2 8.29E-06 
 
CXCR2 3.77E-06 5.70E-07 1 3.77E-06 
      
SMURF1 4.09E-06 3.26E-07 1 4.09E-06 
AD 
     
TNFSF8 3.64E-06 4.53E-06 1 4.53E-06 
CD2AP 2.00E-07 3.55E-09 1 2.00E-07 
 
SULT1A2 5.34E-06 2.00E-10 2 5.34E-06 
BIN1 9.10E-07 1.41E-07 2 9.10E-07 
 
RBM6 5.38E-06 3.96E-07 1 5.38E-06 
      
IRF6 2.47E-06 6.15E-06 9 6.15E-06 
CAD 
     
STARD3 7.43E-06 2.53E-06 4 7.43E-06 
LIPA 4.05E-12 3.74E-12 6 4.05E-12 
 
RPS6KA2 6.36E-09 8.15E-06 22 8.15E-06 
GGCX 5.18E-09 6.38E-09 1 6.38E-09 
 
CARD9 8.92E-06 2.52E-25 2 8.92E-06 
FES 9.29E-07 1.48E-07 1 9.29E-07 
      
           
DM 
          
TP53INP1 6.28E-09 1.10E-07 6 1.10E-07            
Cpg_gene: genes mapped to methylation loci; Simes_methyl_p, gene-based p-value from methylation using Simes test; 
Expr_p, expression p-values from MetaXcan; Total_cpg, total number of methylation lobes combined for this gene; 
Max_conj_p, conjunction test of differential expression and methylation by taking the maximum p.  
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Table 3  Top ten genes for each disease as ranked by their co-fdr  
Cpg_gene Simes_methyl_p Expr_p Total_cpg Simes_conj_p Cofdr 
SCZ 
     
ZSCAN16 6.96E-06 4.64E-22 2 9.28E-22 7.55E-16 
PRRT1 9.66E-03 1.72E-22 1 3.44E-22 1.09E-13 
BTN3A2 7.89E-10 1.43E-18 1 2.87E-18 1.37E-13 
NMB 2.49E-09 1.94E-09 4 2.49E-09 1.71E-09 
KLC1 5.89E-08 8.83E-12 2 1.77E-11 1.60E-08 
BTN1A1 8.47E-01 5.18E-17 1 1.04E-16 2.04E-08 
ARL6IP4 3.75E-10 5.15E-09 3 7.49E-10 6.14E-08 
HIST1H3B 5.83E-03 3.62E-15 1 7.23E-15 9.49E-08 
ABCB9 2.18E-07 1.23E-10 2 2.46E-10 1.45E-07 
SNX19 1.38E-06 5.60E-11 2 1.12E-10 2.68E-07 
      
AD 
     
TOMM40 8.56E-01 1.69E-29 1 3.38E-29 8.04E-24 
DMWD 1.01E-03 2.76E-16 2 5.51E-16 1.05E-14 
CD2AP 3.01E-07 3.55E-09 2 7.10E-09 8.01E-10 
BIN1 9.10E-07 1.41E-07 2 2.82E-07 9.87E-10 
MS4A6A 4.88E-05 2.98E-10 1 5.97E-10 1.06E-08 
MYPOP 5.74E-02 2.68E-11 2 5.35E-11 2.26E-08 
PNOC 1.64E-02 1.23E-10 6 2.46E-10 3.25E-07 
DMPK 1.21E-05 4.76E-06 2 9.52E-06 3.53E-07 
CLPTM1 3.95E-08 2.38E-03 1 7.90E-08 3.58E-07 
MS4A4A 2.18E-01 2.06E-10 1 4.12E-10 5.57E-07 
      
CAD 
     
LIPA 4.05E-12 3.74E-12 6 4.05E-12 1.07E-19 
CELSR2 9.38E-17 3.25E-04 4 1.88E-16 1.86E-16 
PSRC1 1.17E-04 8.21E-19 1 1.64E-18 2.20E-15 
GGCX 5.18E-09 6.38E-09 1 6.38E-09 2.15E-13 
FES 1.05E-06 1.48E-07 1 2.96E-07 3.81E-08 
SIPA1 9.97E-07 2.35E-05 4 1.99E-06 1.55E-07 
SLC22A3 4.20E-04 1.15E-07 1 2.30E-07 5.46E-07 
DHX36 6.01E-05 2.10E-05 2 4.20E-05 8.60E-06 
TAGLN2 4.37E-06 3.38E-05 1 8.73E-06 1.08E-05 
SH2B3 2.57E-05 1.41E-05 1 2.57E-05 2.04E-05 
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DM 
TP53INP1 6.28E-09 1.10E-07 6 1.26E-08 3.58E-10 
JAZF1 5.52E-08 3.49E-03 1 1.10E-07 1.84E-04 
CAMK1D 6.61E-01 1.61E-06 1 3.21E-06 3.48E-04 
PCBD2 2.18E-05 4.93E-04 1 4.36E-05 4.24E-04 
UTS2 3.05E-02 9.61E-06 2 1.92E-05 5.55E-04 
ABCB9 9.52E-05 8.68E-05 1 9.52E-05 1.09E-03 
UBE2E2 1.86E-06 1.64E-03 1 3.72E-06 2.58E-03 
KCNK17 1.93E-04 2.12E-04 2 2.12E-04 2.91E-03 
ANK1 4.35E-06 5.54E-03 4 8.71E-06 3.00E-03 
COPA 1.10E-03 9.49E-04 1 1.10E-03 2.00E-02 
      
IBD 
     
HLA-DRB5 1.15E-31 1.03E-01 4 2.29E-31 2.11E-24 
CARD9 8.92E-06 2.52E-25 2 5.05E-25 1.32E-20 
HLA-DQB2 6.43E-13 2.98E-15 3 5.96E-15 5.37E-19 
FAM8A1 1.13E-24 3.08E-01 1 2.27E-24 1.93E-18 
APEH 3.08E-10 4.02E-20 7 8.04E-20 2.65E-18 
LIME1 4.43E-09 8.13E-16 6 1.63E-15 2.06E-16 
ZGPAT 4.28E-11 1.35E-14 3 2.71E-14 3.58E-15 
ORMDL3 1.23E-12 1.48E-12 4 1.48E-12 5.41E-15 
SLC22A5 8.96E-11 1.52E-12 2 3.04E-12 3.14E-13 
STMN3 9.98E-09 1.94E-12 5 3.89E-12 3.50E-13 
The null hypothesis is the global null, i.e. the gene is not associated with methylation or expression changes. Cpg_gene: 
genes mapped to methylation loci; Simes_methyl_p, gene-based p-value from methylation using Simes test; Expr_p, 
expression p-values from MetaXcan; Total_cpg, total number of methylation lobes combined for this gene; Simes_conj_p, 
p-value by Simes test (testing the global null that the gene is not associated with methylation or expression changes); 
Cofdr, co-false discovery rate with respect to the global null. 
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Table 4   Differential expression within top methylation loci 
  Fisher (diff expr)  Simes (diff expr) 
SCZ 5.95E-113 5.30E-17 
AD 1.20E-14 1.20E-14 
CAD 4.68E-27 3.36E-11 
DM 2.09E-11 5.48E-07 
IBD 2.01E-184 2.09E-18 
Fisher (diff expr), Fisher’s method for combining expression p-values from top methylation loci; Simes (diff expr), Simes 
method for combining expression p-values. 
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Table 5  Correlation between effect sizes of differential methylation and expression  
    SCZ AD CAD DM IBD 
Overall Pearson cor -0.571  0.462  0.065  0.200  -0.065  
 Pearson cor p 1.79e-4 0.211  0.850  0.704  0.619  
 Spearman cor -0.522  0.527  -0.018  -0.290 0.093  
 Spearman cor p 7.74e-4 0.145  0.957  0.577  0.475  
 Opp sign/total 27/38 2/9 4/11 2/6 28/61 
 Binomial test p  0.014  0.180  0.549  0.688  0.609  
       
Promotor region Promoter_region cor -0.611  0.310  -0.352  0.200  -0.017  
 Promoter_region cor p 5.46e-3 0.690  0.648  0.800  0.926  
 Spearman cor -0.630  -0.200  -0.632  -0.400 0.106  
 Spearman cor p 4.71e-3 0.917  0.368  0.750  0.556  
 Opp sign/total 15/19 1/4 2/4 2/4 16/33 
 Binomial test p 
(one-tailed) 
0.010  0.938  0.688  0.688  0.636  
 Binomial test p 
(two-tailed) 
0.019  0.625  1 1 1 
       
Non-promotor 
region 
Other regions cor -0.540  0.650  0.475  NA -0.082  
 Other regions cor p 0.017  0.235  0.281  NA 0.677  
 Spearman cor -0.246  0.900  0.595  NA 0.016  
 Spearman cor p 0.309  0.083  0.250  NA 0.936  
 Opp sign/total 12/19  1/5 2/7 0/2 12/28 
  Binomial test p 0.359  0.375  0.453  0.500  0.572  
 
Methylation probes are grouped by genes and their locations for computing correlations. Effect sizes are averaged if a gene 
is represented by multiple methylation probes. Overall cor, overall correlation regardless of locations; cor, correlation; Opp 
sign/total, effect sizes with opposite signs/total; Binomial test p (one-tailed), one-tailed binomial test for opposite direction 
of effect sizes.  
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